TriangleNCT00113763 · OUTCOME
Time to Disease Progression
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
What was measured
Kaplan-Meier estimates of median time from randomization to disease progression or death due to disease progression (whichever occurs first)
Analysis population: Intention-to-treat
Groups in this outcome
Panitumumab Plus BSC
Panitumumab plus best supportive care (BSC). Panitumumab was administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease or were unable to tolerate study drug.
BSC Alone
Best supportive care defined as the best care available as judged appropriate by the investigator and according to institutional guidelines, including antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care does not include anti-neoplastic chemotherapy.
| Group | Source count |
|---|---|
| Panitumumab Plus BSC | 231 |
| BSC Alone | 232 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Panitumumab Plus BSC | 8.0 | Not reported | 7.9 | 8.9 | Not reported |
| BSC Alone | 7.3 | Not reported | 7.1 | 7.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.9
- upper Limit
- 8.9
- value
- 8.0
- group Id
- OG001
- lower Limit
- 7.1
- upper Limit
- 7.7
- value
- 7.3
- denoms
- counts
- group Id
- OG000
- value
- 231
- group Id
- OG001
- value
- 232
- units
- Participants
- description
- Kaplan-Meier estimates of median time from randomization to disease progression or death due to disease progression (whichever occurs first)
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Panitumumab plus best supportive care (BSC). Panitumumab was administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease or were unable to tolerate study drug.
- id
- OG000
- title
- Panitumumab Plus BSC
- description
- Best supportive care defined as the best care available as judged appropriate by the investigator and according to institutional guidelines, including antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care does not include anti-neoplastic chemotherapy.
- id
- OG001
- title
- BSC Alone
- param Type
- MEDIAN
- population Description
- Intention-to-treat
- reporting Status
- POSTED
- time Frame
- From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
- title
- Time to Disease Progression
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice